pe
pep-10975 v1 CC-BY-SA-4.0

Abaloparatide: Tymlos bone-building osteoporosis drug

A lab-made injectable drug that stimulates the body to build new bone, used to treat osteoporosis in people at high risk of fractures; FDA-approved.

statusbioassayed targetPTH1R length36 aa refs5
status 5 / 5
prediction metrics openfold3-mlx 0.3.1
ipTM0.833
pTM0.661
avg pLDDT46.8
ranking score0.947
STRUCTURE · PEP-10975 × PTH1R
ranking0.947
target interface 4.5Å peptide drag rotate · ctrl+scroll zoom · right-click pan
openfold3-mlx 0.3.1 · mmCIF ↓ download
sequence36 aa
1510152025303536
AVSEHQLLHDKGKSIQDL RRRELLEKLLAKNLGPHR
in the news 1 article
overview readme

What this is

Abaloparatide (brand name Tymlos) is an FDA-approved injectable medication used to treat osteoporosis — a condition in which bones become thin and fragile, leading to fractures. It belongs to a class of drugs called osteoanabolics, meaning it actively stimulates the body to build new bone rather than just slowing bone loss. Abaloparatide is a synthetic 36-residue peptide designed from the N-terminal region of parathyroid hormone-related protein (PTHrP), a natural hormone involved in bone and calcium regulation. It was approved by the FDA in April 2017 for postmenopausal women with osteoporosis at high risk of fracture, and a subsequent approval extended the indication to men with osteoporosis.

History

The origins of abaloparatide trace back to the discovery of PTHrP in the 1980s as the molecule responsible for humoral hypercalcemia of malignancy — a condition in which certain cancers release a hormone-like factor that causes dangerously elevated calcium levels. PTHrP was found to share significant structural homology with parathyroid hormone (PTH) at the N-terminus and to act on the same receptor (PTH1R), but with distinct physiological roles in bone development, cartilage, and lactational calcium metabolism.

The therapeutic hypothesis pursued by Radius Health was that targeted substitutions in the PTHrP 1–34 sequence could engineer preferential binding to a specific receptor conformation — the so-called RG state — to produce a cleaner anabolic effect than existing PTH analogs. Hattersley and colleagues (Endocrinology 2016) characterized this binding selectivity in detail, showing that abaloparatide engages the RG conformation of PTH1R more preferentially than PTH 1-34, which produces a more transient intracellular signaling response. The pivotal Phase 3 ACTIVE trial results were reported by Miller and colleagues in JAMA in 2016, and the FDA granted approval on April 28, 2017. The original label carried a boxed warning for osteosarcoma risk — derived from rat carcinogenicity studies shared with the teriparatide class — as well as a cumulative lifetime use restriction; the FDA removed both in 2022 following accumulated post-marketing data showing no human osteosarcoma signal. The ACTIVExtend trial (Cosman and colleagues, Mayo Clinic Proceedings 2017) subsequently established the sequential treatment paradigm: abaloparatide for the anabolic phase followed by an antiresorptive agent to consolidate gains. The ATOM trial later demonstrated efficacy and safety in men with osteoporosis, leading to the expanded indication.

What it does

Abaloparatide tells bone-building cells (osteoblasts) to increase their activity, shifting the balance of bone remodeling toward formation. Given once daily, it produces a pulsatile signal at the PTH1 receptor that favors new bone synthesis over bone breakdown — the opposite of what happens with continuous PTH1R activation (as in primary hyperparathyroidism, which is catabolic). The practical result, demonstrated in clinical trials, is measurable increases in bone mineral density at the spine, hip, and femoral neck, and a significant reduction in the risk of vertebral and non-vertebral fractures in people with osteoporosis. Because abaloparatide's anabolic effect depends on the once-daily pulsatile schedule, the gains begin to reverse after discontinuation unless an antiresorptive medication (such as a bisphosphonate) is started to consolidate the newly built bone.

Evidence

  • Human: Strong. The Phase 3 ACTIVE trial (Miller and colleagues, JAMA 2016) randomized 2,463 postmenopausal women at high fracture risk to abaloparatide, open-label teriparatide, or placebo for 18 months; abaloparatide significantly reduced new morphometric vertebral fractures and non-vertebral fractures versus placebo, with bone mineral density gains at the lumbar spine, total hip, and femoral neck that were comparable to or greater than teriparatide, alongside a lower rate of treatment-emergent hypercalcemia. The ACTIVExtend trial (Leder and colleagues, Journal of Bone and Mineral Research 2019) showed that patients who transitioned from abaloparatide to alendronate preserved and extended fracture-risk reduction over an additional period. The ATOM trial established comparable efficacy and safety in men with osteoporosis. A 2025 network meta-analysis (Höppner and colleagues, Nature Communications) and multiple systematic reviews and Bayesian network meta-analyses confirm the fracture-risk reduction and BMD gains in postmenopausal women; a 2025 network meta-analysis in Frontiers in Endocrinology addressed the male osteoporosis indication.
  • Animal: Extensive. Ovariectomized-rat and orchiectomized-rat models, as well as disuse and glucocorticoid models, characterize abaloparatide's anabolic effects and receptor pharmacology, including bone histomorphometry data from the ACTIVE trial's biopsy substudy (Moreira and colleagues, Bone 2016).
  • In vitro / mechanistic: Sato and colleagues (JBMR Plus 2021) compared intracellular signaling kinetics of abaloparatide, teriparatide, and long-acting PTH at PTH1R, providing mechanistic context for their distinct clinical profiles. The RG-conformation selectivity story is further elaborated in Leder's review (Current Osteoporosis Reports 2017).

Known effects

  • Reduced vertebral fracture risk — FDA-approved (Phase 3, ACTIVE trial)
  • Reduced non-vertebral fracture risk — FDA-approved (Phase 3, ACTIVE trial)
  • Increased bone mineral density at lumbar spine, total hip, and femoral neck — FDA-approved (Phase 3, ACTIVE trial; ACTIVExtend follow-on)
  • Treatment of osteoporosis in men — FDA-approved (ATOM trial)
  • Sequential anabolic-antiresorptive therapy — supported by ACTIVExtend: transitioning to alendronate after abaloparatide preserves and extends fracture-risk reduction

Safety signals

Adverse events reported in the ACTIVE trial include injection-site reactions, dizziness and orthostatic hypotension (particularly after the first dose), nausea, palpitations, and transient hypercalcemia. Treatment-emergent hypercalcemia occurred at a lower rate with abaloparatide than with the open-label teriparatide comparator in ACTIVE (Miller and colleagues, JAMA 2016), consistent with the proposed RG-conformation selectivity mechanism. A dedicated cardiovascular safety analysis of ACTIVE (reported separately) found no increase in serious cardiac events. Abaloparatide shares the PTH1R-agonist class cautions: the drug is not indicated in patients with conditions associated with elevated baseline osteosarcoma risk (Paget's disease of bone, prior skeletal radiation, open epiphyses, unexplained elevated alkaline phosphatase) and should be used with caution in severe renal impairment. The original boxed warning for osteosarcoma risk — which was based on Fischer 344 rat carcinogenicity data and was never grounded in a human signal — was removed by the FDA in 2022, in parallel with the equivalent action on teriparatide, following post-marketing surveillance showing no osteosarcoma cases attributable to PTH1R agonists.

Regulatory status

  • US: Prescription-only. FDA-approved (April 28, 2017) for postmenopausal women with osteoporosis at high risk of fracture; indication subsequently expanded to men with osteoporosis. Boxed warning and cumulative lifetime use cap removed by FDA in 2022. Marketed as Tymlos.
  • Canada: Approved by Health Canada.
  • UK: MHRA approval obtained in 2022.
  • EU: The EMA's initial CHMP opinion in 2018 was negative; the original EU marketing authorization application was withdrawn. Access in EU member states has varied by country.
  • Japan: Approved; Phase 3 data in Japanese patients (ACTIVE-J) are available.
  • WADA: Abaloparatide is not specifically listed on the current WADA Prohibited List, but its anabolic bone activity and PTH1R-axis pharmacology would draw scrutiny in performance contexts; athletes with documented osteoporosis may use it under appropriate therapeutic use exemption documentation.

Myths and misconceptions

  • "Abaloparatide is just a generic or biosimilar version of teriparatide." — It is a distinct molecule. Teriparatide is a synthetic copy of human PTH 1–34; abaloparatide is an engineered analog of PTHrP 1–34, a related but different hormone. It has its own sequence, receptor pharmacology (RG-conformation selectivity), pen device, and regulatory history. It is a brand-name drug (Tymlos), not a generic.
  • "The boxed warning means abaloparatide causes bone cancer." — The original boxed warning came from rat carcinogenicity studies at high lifetime exposures — the same rat data that triggered the original teriparatide warning. Over five years of post-marketing surveillance after the 2017 US approval identified no human osteosarcoma cases, and the FDA removed the warning in 2022. Patients with conditions that already elevate osteosarcoma risk (Paget's disease, prior bone radiation, open epiphyses) remain a labeled caution.
  • "Building bone with abaloparatide means the gains are permanent." — BMD gains are rapidly lost after discontinuation unless an antiresorptive agent is started to consolidate them. The ACTIVExtend trial was designed specifically to demonstrate the value of sequential therapy: the anabolic phase with abaloparatide, followed by alendronate, preserved and extended fracture-risk reduction beyond what abaloparatide alone achieves.

Mechanism

Abaloparatide binds and activates PTH1R (the parathyroid hormone type 1 receptor) on osteoblasts and their precursors. The key pharmacological distinction from teriparatide (PTH 1-34) is conformational selectivity: abaloparatide preferentially engages the RG conformation of PTH1R — a receptor state associated with more transient cAMP/PKA signaling — whereas PTH 1-34 binds more readily to both the RG and R0 (prolonged signaling) conformations. This conformational preference was characterized by Hattersley and colleagues (Endocrinology 2016) and elaborated in comparisons by Sato and colleagues (JBMR Plus 2021). The hypothesis is that more transient PTH1R activation drives a wider anabolic window — more net osteoblast activity relative to osteoclast stimulation — and produces less sustained hypercalcemia than PTH 1-34, both of which are directionally supported by the ACTIVE trial data.

Downstream signaling from pulsatile PTH1R activation suppresses sclerostin, activates the Wnt/β-catenin pathway, and promotes osteoblast proliferation, differentiation, and survival. The pulsatile once-daily schedule is mechanistically essential: continuous PTH1R stimulation drives net bone resorption rather than formation (as seen in primary hyperparathyroidism), so the pharmacology is schedule-dependent.

The raw stored sequence (AVSEHQLLHDKGKSIQDLRRRELLEKLLAKNLGPHR, 36 residues) represents the primary peptide chain of the synthetic analog; abaloparatide does not carry lipid or polymer conjugates, so no modifications are absent from the linear sequence.

Open questions

  • Head-to-head fracture endpoint data versus teriparatide and romosozumab remain limited; the ACTIVE comparison was open-label for teriparatide only, and indirect network meta-analyses have methodological caveats (Leder, Current Osteoporosis Reports 2017; network meta-analyses 2025).
  • Optimal sequencing within the expanded osteoanabolic toolkit — three anabolic agents are now FDA-approved (teriparatide, abaloparatide, romosozumab) — is still being worked through by guideline bodies.
  • A transdermal microneedle-patch formulation (abaloparatide-sMTS) did not meet non-inferiority versus subcutaneous injection in Phase 3 trials; whether further device development can close the gap is unresolved.
  • Abaloparatide has not been studied for glucocorticoid-induced osteoporosis to the degree teriparatide has, leaving a gap in the evidence base for this common indication.
  • Repeat-course efficacy — whether a second treatment course after antiresorptive consolidation delivers additional benefit — has not been adequately studied.

Related peptides

Abaloparatide acts at the same PTH1 receptor as teriparatide (synthetic PTH 1–34), the first FDA-approved osteoanabolic peptide, and the two are frequently compared in clinical practice and meta-analyses (Leder and colleagues, Journal of Bone and Mineral Research 2019). Romosozumab, a sclerostin-inhibiting monoclonal antibody, represents a third FDA-approved osteoanabolic mechanism and sits alongside both peptides in current osteoporosis guidelines. Parathyroid hormone-related protein (PTHrP), the endogenous precursor whose N-terminal sequence provided the template for abaloparatide's design, plays roles in lactational calcium mobilization, vascular smooth muscle, and skeletal development distinct from PTH's primary calcium-regulatory role.

Hypotheses4 directions▾ collapse

Research directions for this peptide, selected from the current sources — hypotheses you can explore and model. None of it is proven yet; tap any one to see the full thinking.

openupdated 2026-06-05

Could abaloparatide replace missing parathyroid hormone in patients with underactive parathyroid glands more safely than existing options, by causing less kidney calcium loss?

People with hypoparathyroidism must take calcium and vitamin D every day for life, often with side effects affecting the kidneys. A safer hormone replacement that maintains calcium without damaging the kidneys would improve long-term health outcomes for thousands of patients.

The hypothesis
Abaloparatide's preferential RG-state PTH1R binding could make it effective for treating hypoparathyroidism in patients who are refractory to PTH(1-34) replacement, because RG-state preference maintains longer anabolic cAMP signaling even at low receptor occupancy, compensating for insufficient endogenous PTH levels without driving hypercalciuria.
Why it’s plausible
Hypoparathyroidism requires PTH replacement to maintain calcium homeostasis; teriparatide (PTH 1-34) is used off-label but causes hypercalciuria and bone turnover side effects because it activates both RG and R0 receptor conformations. Abaloparatide was designed to favor the RG state, which prolongs cAMP signaling through beta-arrestin-independent pathways. Lower hypercalciuria risk at equivalent calcium-mobilizing doses would represent a clinically meaningful advantage in hypoparathyroidism management.
Why it matters
Hypoparathyroidism has limited approved treatment options; a PTH analogue with a lower hypercalciuria profile at equivalent PTH1R-activating doses would address the primary dose-limiting toxicity of current replacement therapy.
Plausibility.70
Novelty.70
Impact.75
Basis · grounding3 papers
[1]
paper
Abaloparatide preferentially binds RG conformation of PTH1R, generating prolonged cAMP signaling relative to teriparatide.
doi: 10.1210/en.2015-1726
[2]
paper
PTH1R signaling events in osteocytes downstream of PTH1R involve distinct cAMP-dependent cascades; receptor conformation state influences this.
doi: 10.1002/jbm4.10441
[3]
paper
Clinical abaloparatide data in osteoporosis establishes PTH1R activation capacity; the hypoparathyroidism indication is a logical mechanistic extension.
doi: 10.1001/jama.2016.11136
openupdated 2026-06-05

Do the three consecutive arginine residues in abaloparatide cause the drug to stick to negatively charged molecules in bone before it even reaches the receptor, giving bone tissue a higher effective dose than kidney?

If bone matrix pre-concentrates abaloparatide, drug designers could amplify this effect by adding or optimizing the basic cluster to make an even more bone-targeted version, possibly achieving greater fracture reduction at a lower total dose with reduced kidney effects.

The hypothesis
The three consecutive arginine residues at positions 19-21 (RRR) in abaloparatide's sequence AVSEHQLLHDKGKSIQDLRRRELLEKLLAKNLGPHR create a polybasic cluster that drives transient electrostatic pre-association with negatively charged proteoglycan residues on the bone matrix surface, concentrating the peptide near osteoblast PTH1R and contributing to its locally amplified anabolic effect in bone relative to kidney.
Why it’s plausible
Polybasic clusters (RRR, KKKK) are known heparin-binding motifs that enable electrostatic interactions with sulfated proteoglycans in the extracellular matrix. Bone matrix is rich in osteocalcin-associated proteoglycans and hydroxyapatite with negatively charged surfaces. Kidney tubular cells lack the dense proteoglycan matrix of bone. If the RRR cluster drives bone-matrix association, abaloparatide would be locally concentrated near osteoblasts, amplifying anabolic PTH1R signaling in bone relative to kidney PTH1R, which could partly explain the favorable bone-to-kidney effect ratio compared to teriparatide (PTH 1-34), which lacks a polybasic cluster of this density.
Why it matters
Demonstrating matrix-driven local concentration as a mechanism for bone selectivity would be a new principle for anabolic peptide targeting and would explain why removing the RRR segment reduces bone efficacy disproportionately to receptor affinity changes.
Plausibility.60
Novelty.75
Impact.70
Basis · grounding2 papers · 1 computed/note
[1]
sequenceAVSEHQLLHDKGKSIQDLRRRELLEKLLAKNLGPHR contains RRR at positions 19-21, a classical heparin-binding motif; verified directly from the sequence.
[2]
paper
Binding selectivity of abaloparatide for PTH1R conformations and downstream signaling; bone vs. kidney selectivity is discussed.
doi: 10.1210/en.2015-1726
[3]
paper
Clinical vertebral and non-vertebral fracture reduction with abaloparatide; superior bone efficacy relative to teriparatide has been observed.
doi: 10.1001/jama.2016.11136
openupdated 2026-06-05

If the three positively charged arginines in abaloparatide cause it to stick non-specifically to tissues and clear too fast, could replacing them with a single modified amino acid extend its duration in the bloodstream?

Abaloparatide currently requires a daily injection, which is a major barrier to long-term use. A version that stays active for a week would dramatically improve patient adherence and potentially help more people maintain bone density and avoid fractures.

The hypothesis
Substituting the three-arginine cluster (RRR, positions 19-21) in abaloparatide with a single non-coded cationic residue of intermediate steric bulk would reduce heparin-binding-driven non-specific matrix association without losing anabolic PTH1R signaling, improving the peptide's pharmacokinetic profile by reducing volume of distribution and extending circulating half-life.
Why it’s plausible
Polybasic clusters increase binding to heparan sulfate in vascular walls and extracellular matrices broadly, which can increase volume of distribution and reduce systemic exposure. Abaloparatide is administered daily by subcutaneous injection with a half-life of approximately 1 hour, partly due to rapid tissue distribution. If the RRR cluster drives non-specific matrix sequestration at non-bone sites, reducing its charge density via replacement with a single bulkier cationic residue could reduce this sink effect without eliminating the bone-matrix pre-concentration hypothesis, creating a molecule with better pharmacokinetics for potential longer-interval dosing.
Why it matters
A version of abaloparatide with modified cationic cluster and extended half-life could enable weekly or biweekly dosing, dramatically improving patient adherence for an osteoporosis treatment that is currently a daily injection.
Plausibility.55
Novelty.70
Impact.75
Basis · grounding1 paper · 2 computed/notes
[1]
sequenceRRR at positions 19-21 verified in AVSEHQLLHDKGKSIQDLRRRELLEKLLAKNLGPHR; polybasic clusters are known to increase tissue distribution.
[2]
sourceMean plasma clearance data for related peptides; abaloparatide half-life approximately 1 hour limits dosing interval.
[3]
paper
Hydrogel continuous delivery of abaloparatide achieves bone effects; reduced clearance via modified charge profile would achieve similar sustained exposure from depot injection.
doi: 10.1016/j.ejphar.2021.174409
openupdated 2026-06-05

Is the C-terminal portion of abaloparatide mostly unstructured when it binds its receptor, and does this explain why it preferentially stimulates bone-building over calcium release?

If only the front of the drug locks onto the receptor while the back half remains loose, engineers could redesign the back half to create an even more selective bone builder with fewer side effects related to calcium metabolism.

The hypothesis
Abaloparatide's low complex pLDDT of 46.8 despite a reasonable ipTM of 0.83 indicates that the predicted interface is plausible in overall topology but that large flexible regions of the 36-residue peptide (AVSEHQLLHDKGKSIQDLRRRELLEKLLAKNLGPHR) are disordered at the PTH1R binding site, and the C-terminal helix (residues approximately 22-36, containing the RRRELLEKLLAKNLGPHR segment) may be peripherally positioned without stable receptor contacts.
Why it’s plausible
A pLDDT of 46.8 is low for a bound peptide complex and is characteristic of intrinsic disorder or absence of stable contacts in portions of the chain. The PTH1R N-terminal extracellular domain binds the C-terminal portion of PTH-related ligands in a two-domain binding model, while the N-terminal portion of the peptide inserts into the transmembrane bundle for activation. If the C-terminal segment of abaloparatide is predicted disordered in the complex, it may form less stable contacts with the PTH1R extracellular domain than teriparatide does, consistent with preferential binding to the RG (G protein-coupled) receptor conformation rather than the R0 (uncoupled) conformation, which is the claimed mechanistic basis of its anabolic selectivity.
Why it matters
Low pLDDT in the C-terminal region of abaloparatide at PTH1R would provide structural evidence that the RG-selective binding model is correct, and would indicate that the C-terminal tail is a viable site for engineering improved extracellular domain contacts without disrupting the anabolic signaling bias.
Plausibility.70
Novelty.55
Impact.60
Basis · grounding1 paper · 2 computed/notes
[1]
structureopenfold3-mlx complex pLDDT=46.8, low for a peptide-receptor complex, suggesting substantial disorder in portions of the 36-aa chain at the interface.
[2]
paper
Abaloparatide was explicitly designed for preferential binding to the RG (G protein-coupled) PTH1R conformation over the R0 conformation, predicting differential extracellular domain engagement.
doi: 10.1210/en.2015-1726
[3]
sequenceAVSEHQLLHDKGKSIQDLRRRELLEKLLAKNLGPHR: C-terminal half is highly basic (RRR, K, K, R) and may be disorder-prone in solution and at the receptor.
details expand to inspect
full evidence table2 metrics
metricvaluetool
ipTM 0.8326408863067627 openfold3-mlx
ranking score 0.9470502138137817 openfold3-mlx
structural qualityopenfold3
0
metricvaluenote
gpde0.813global PDE — lower = better
disorder0.297fraction disordered
chain pair ipTM (A, B)0.833interface quality
3-letter notation
Ala-Val-Ser-Glu-His-Gln-Leu-Leu-His-Asp-Lys-Gly-Lys-Ser-Ile-Gln-Asp-Leu-Arg-Arg-Arg-Glu-Leu-Leu-Glu-Lys-Leu-Leu-Ala-Lys-Asn-Leu-Gly-Pro-His-Arg
recipeopenfold3-mlx 0.3.1
parametervalue
modelopenfold3-mlx 0.3.1
weights
hardware
mlx version
python
random seed
msa strategy
diffusion samples1
runtime837s
predicted bymlx@peptide
predicted at2026-05-03
citationbibtex
peptidemodel (2026). Abaloparatide: Tymlos bone-building osteoporosis drug (pep-10975, v1). PeptideModel. https://peptidemodel.com/card/pep-10975
@peptide{pep10975,
  sequence = {AVSEHQLLHDKGKSIQDLRRRELLEKLLAKNLGPHR},
  target   = {pth1r},
  author   = {peptidemodel},
  year     = {2026},
  status   = {bioassayed}
}
related peptides 5 by signal overlap
clinical trials 24 on ct.gov · 2 on EUCTR · checked 2026-05-09
ct.gov trials 24
with results 10
EUCTR 2
PubMed RCT 35
by phase
1phase 12phase 24phase 32phase 41no phase
by status
3completed1recruiting1active2not yet recruiting2withdrawn1unknown
references 5 papers
discussion no comments
sign in to comment
peptidemodel.com CC-BY-SA-4.0 research only · not for human use